Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome.
- Author:
Liqun, LV
;
Yi, LIU
;
Yongyu, SUN
;
Kan, TAN
- Publication Type:Journal Article
- MeSH:
Androgen Antagonists/therapeutic use;
Androstenedione/blood;
Body Mass Index;
Cyproterone Acetate/*therapeutic use;
Drug Therapy, Combination;
Hypoglycemic Agents/*therapeutic use;
Insulin Resistance;
Metformin/*therapeutic use;
Polycystic Ovary Syndrome/*drug therapy
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2005;25(2):194-7
- CountryChina
- Language:English
-
Abstract:
In order to explore the effects of metformin combined with cyproterone acetate (CPA) on the clinical features, endocrine and metabolism of the patients with polycystic ovarian syndrome (PCOS), 50 cases of non-obese PCOS were randomly subjected to CPA (CPA treatment group, n = 25) and CPA+ metformin (n = 25) treatment for 6 months. Before and after treatment the body mass index (BMI), waist : hip ratio (WHR), ovarian volume, serum gonadotrophin, androgen and sex hormone-binding globulin (SHBG) levels, and fasting lipid, glucose and insulin levels were measured. The results showed that all of the parameters in two groups were similar before treatment. After treatment for 6 months in the CPA+ metformin group, BMI and WHR were significantly decreased, while insulin sensitivity was significantly decreased as Compared with those before treatment. In CPA group, no significant changes were found before and after treatment. Combined use of CPA and metformin could result in the reduction of serum androstenedione and increases of serum SHBG levels as compared with the CPA treatment alone. It was concluded that combined use of CPA and metformin could improve the insulin sensitivity, and further suppress the hyperandrogenism in non-obese women with PCOS.
